← Research library

Oral Cerluten with injected Cortexin in older women with vascular encephalopathy

Comparison in people · 2007

What was studied
167 women aged 65–74 with stage II dyscirculatory encephalopathy. Usual care 68, usual care plus Cortexin 45, usual care plus Cortexin and Cerluten 54.
Main finding
At days 30–31, psychosomatic severity scores were 18.04 with Cerluten plus Cortexin, 24.13 with Cortexin alone as an adjunct, and 30.49 with usual care. All three groups improved.

Reported findings and study design

Three usual-care groups: care alone (68), plus injected Cortexin (45), or plus injected Cortexin and oral Cerluten (54). Both peptide arms later took a 60-day Cerluten course.

Population or model 167 women aged 65–74 with stage II dyscirculatory encephalopathy. Usual care 68, usual care plus Cortexin 45, usual care plus Cortexin and Cerluten 54.

Dose, route and schedule

Both peptide arms received Cortexin 10 mg intramuscularly once daily for 10 days. The combined arm added Cerluten two tablets twice daily for 30 days. One month later, both peptide arms received Cerluten two tablets twice daily for 60 days. The Cerluten mass per tablet is unspecified.

Protocol source ↗ · Russian author-abstract transcription, methods and Tables 2 and 5

Results · Russian author-abstract transcription, methods and Tables 2 and 5
MeasureResultComparison, timing and statistics
Psychosomatic severity · days 30–3118.04 combined, 24.13 Cortexin, 30.49 usual careLower values indicate lower severity. Baseline means 82.52, 80.12 and 81.52.
Recovery index · days 30–3185.4 combined, 78.6 Cortexin, 68.7 usual careTable 2. A separate prose value for the combined group is 88.32.
Repeat medical visits · six months23/54, 31/45 and 57/68By original group order: combination, Cortexin, usual care. Both original peptide arms received Cerluten during follow-up. Table 5 lists repeat medical visits as a proportion of each group.
Table 2 · psychosomatic severity scores
Table 2 · psychosomatic severity scores
Initial treatmentBaselineDays 10–11Days 20–21Days 30–31
Usual care81.52 ± 2.7563.34 ± 1.7540.43 ± 1.2430.49 ± 3.40
Usual care + Cortexin80.12 ± 5.3260.15 ± 1.5038.09 ± 1.3324.13 ± 3.16
Usual care + Cortexin + Cerluten82.52 ± 3.4758.30 ± 1.9035.24 ± 2.3218.04 ± 4.23

Means and ± values as reproduced. The available transcription flattens the p-value columns, so pairwise p-values are omitted.

All groups improved. The comparison cannot establish how oral Cerluten would perform by itself or explain the later differences in medical visits.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • The accessible author abstract does not describe random allocation or masking. The severity scale was developed within the study. The initial comparison had no oral Cerluten-only arm.
  • At follow-up both prior peptide arms received Cerluten, so earlier treatment and group differences may account for some of the difference in repeat visits.
  • The accessible transcription omits a clear harms inventory. Follow-up figures do not establish prevention of stroke or dementia.

Source details

Dissertation author abstract

Russian author-abstract transcription, methods and Tables 2 and 5

Sources checked

Added to the library

Citation

Human comparative studyRussian-language source

G. L. Zhernakov. Oral Cerluten with injected Cortexin in older women with vascular encephalopathy St Petersburg, 2007 dissertation author abstract, Russian transcription

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards